Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis.
Dong LuoXinning WangClemens BurdaJames P BasilionPublished in: Cancers (2021)
The last decade has witnessed the booming of preclinical studies of gold nanoparticles (AuNPs) in biomedical applications, from therapeutics delivery, imaging diagnostics, to cancer therapies. The synthetic versatility, unique optical and electronic properties, and ease of functionalization make AuNPs an excellent platform for cancer theranostics. This review summarizes the development of AuNPs as contrast agents to image cancers. First, we briefly describe the AuNP synthesis, their physical characteristics, surface functionalization and related biomedical uses. Then we focus on the performances of AuNPs as contrast agents to diagnose cancers, from magnetic resonance imaging, CT and nuclear imaging, fluorescence imaging, photoacoustic imaging to X-ray fluorescence imaging. We compare these imaging modalities and highlight the roles of AuNPs as contrast agents in cancer diagnosis accordingly, and address the challenges for their clinical translation.
Keyphrases
- fluorescence imaging
- high resolution
- papillary thyroid
- gold nanoparticles
- magnetic resonance imaging
- magnetic resonance
- photodynamic therapy
- contrast enhanced
- squamous cell
- childhood cancer
- mental health
- deep learning
- reduced graphene oxide
- stem cells
- cell therapy
- machine learning
- mass spectrometry
- squamous cell carcinoma
- positron emission tomography
- physical activity
- case control
- pet ct